Maze Therapeutics

Maze Therapeutics is a clinical-stage biopharmaceutical company that uses human genetics to develop novel small molecule precision medicines. Founded in 2018, it was established with the vision of building the next generation precision medicines company. Its work spans human genetics, functional genomics, target identification and validation, small molecule drug discovery and precision medicine.

At the centre of its research is the Maze Compass™ platform, a proprietary system that integrates human genetics and functional genomics to identify and validate therapeutic targets addressing the underlying genetic drivers of disease. The company currently has three clinical-stage programs developing precision medicines for renal, cardiovascular and related metabolic conditions, alongside several earlier-stage programs in drug discovery.

Maze Therapeutics describes its team as "genetic navigators" and states core values of Further Together, Impact Obsessed and Stand True, with an emphasis on collaboration, scientific rigour and making a meaningful difference in patients' lives. The company operates in the biopharmaceutical, renal disease, cardiovascular disease, metabolic disease and precision medicine fields.